See more : LBT Innovations Limited (LBT.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Alzamend Neuro, Inc. (ALZN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alzamend Neuro, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Sichuan Kelun Pharmaceutical Co., Ltd. (002422.SZ) Income Statement Analysis – Financial Results
- Koyou Rentia Co., Ltd. (7081.T) Income Statement Analysis – Financial Results
- Vertex Minerals Limited (VTXXF) Income Statement Analysis – Financial Results
- AGS Transact Technologies Limited (AGSTRA.NS) Income Statement Analysis – Financial Results
- BOCOM Schroders CSI OS China(QDII-LOF)A (164906.SZ) Income Statement Analysis – Financial Results
Alzamend Neuro, Inc. (ALZN)
About Alzamend Neuro, Inc.
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 50.74K | 23.07K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -50.74K | -23.07K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 6.46M | 7.45M | 5.20M | 1.31M | 1.07M | 3.70M | 323.40K | 275.05K | 0.00 |
| General & Administrative | 3.24M | 6.68M | 7.12M | 3.64M | 3.35M | 1.31M | 545.12K | 942.51K | 69.46K |
| Selling & Marketing | 247.33K | 742.60K | 17.65K | 0.00 | 0.00 | 0.00 | 29.91K | 330.84K | 0.00 |
| SG&A | 3.48M | 7.42M | 7.12M | 3.64M | 3.35M | 1.31M | 575.03K | 1.27M | 69.46K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 9.94M | 14.87M | 12.32M | 4.95M | 4.42M | 5.01M | 898.43K | 1.55M | 69.46K |
| Cost & Expenses | 9.94M | 14.87M | 12.32M | 4.95M | 4.42M | 5.01M | 898.43K | 1.55M | 69.46K |
| Interest Income | 0.00 | 7.70 | 46.52 | 1.71K | 13.93K | 146.39K | 33.23K | 21.50K | 0.00 |
| Interest Expense | 10.10K | 7.70K | 46.52K | 158.80K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 50.74K | 23.07K | 3.55K | 4.95M | 4.42M | 5.01M | 898.43K | 1.55M | 69.46K |
| EBITDA | -9.89M | -14.85M | -12.32M | 0.00 | 0.00 | 0.00 | 7.34K | -21.50K | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.94M | -14.87M | -12.32M | -4.95M | -4.42M | -5.01M | -898.43K | -1.55M | -69.46K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -10.10K | -7.70K | -42.52K | -94.68K | 13.93K | 146.39K | -33.23K | -21.50K | 0.00 |
| Income Before Tax | -9.95M | -14.88M | -12.36M | -5.05M | -4.41M | -4.86M | -931.66K | -1.57M | -69.46K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -144.83K | 42.52K | 157.10K | -13.93K | -146.39K | -898.43K | -21.50K | 0.00 |
| Net Income | -9.95M | -14.88M | -12.40M | -5.20M | -4.40M | -4.86M | -931.66K | -1.57M | -69.46K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -14.72 | -22.89 | -20.92 | -10.75 | -9.26 | -12.40 | -1.64 | -8.18 | -0.42 |
| EPS Diluted | -14.70 | -22.89 | -20.88 | -10.74 | -9.25 | -12.40 | -1.64 | -8.18 | -0.42 |
| Weighted Avg Shares Out | 676.00K | 650.00K | 593.00K | 484.00K | 475.00K | 392.00K | 568.70K | 192.00K | 165.00K |
| Weighted Avg Shares Out (Dil) | 676.57K | 650.13K | 593.97K | 484.33K | 475.02K | 392.29K | 568.70K | 192.01K | 165.30K |
Alzamend Neuro Contracts with Altasciences and iResearch Atlanta to Manage and Conduct Its Phase IIA Study in Patients with Alzheimer’s
ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced that it contracted with Altasciences Clinical Kansas (“Altasciences”) and iResearch Atlanta, LLC...
Alzamend Neuro Appoints Dr. Terri Hunter to Its Scientific Advisory Board
ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced the appointment of Dr. Terri Hunter, Ph.D., a Technology Transfer Specialist, to...
Alzamend Neuro Announces Full Data Set From Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced that it has received the full data set from its Phase 1...
Are These Penny Stocks Worth Buying Right Now?
Can penny stocks continue to show positive momentum in 2022? The post Are These Penny Stocks Worth Buying Right Now?
Here's 3 Top Penny Stocks For Your January Watchlist
Can penny stocks continue to show momentum next year? The post Here's 3 Top Penny Stocks For Your January Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market
Alzamend reported positive results from its phase 1 study using AL001 for the treatment of patients with Alzheimer's Disease.
Alzamend Neuro Announces Positive Topline Data from Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
TAMPA, Fla.--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced that it has received positive topline data from its Phase 1...
Why Alzamend Neuro Stock Soared Today
The company hopes to advance the standard of care for people with dementia.
Penny Stocks To Buy According To 5 Analysts With 55%-246% Targets
5 penny stocks analysts say are a buy right now with hefty price targets. The post Penny Stocks To Buy According To 5 Analysts With 55%-246% Targets appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Best Penny Stocks To Buy? 5 To Watch With Potential Catalysts This Week
5 penny stocks to watch this week The post Best Penny Stocks To Buy? 5 To Watch With Potential Catalysts This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Source: https://incomestatements.info
Category: Stock Reports